← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1 · 임상 갱신 필요 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV28행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
ADCLimited DatastalePhase 2
Daunorubicin Hydrochloride (Daunorubicin Hydrochloride)
Alliance for Clinical Trials in On…·Acute Myeloid Leukemia
129 trials·t½ 3 h
Overview
Program
Daunorubicin Hydrochloride
Overview
Company
Alliance for Clinical Trials in Oncology
Overview
Modality
ADC
Overview
Target
Acute Myeloid Leukemia
Overview
Indication
Acute Myeloid Leukemia
Overview
Phase
PHASE_2
Overview
Status
DISCONTINUED
Overview
Content status
Limited Data
Overview
Data Confidence
Data Confidence · Low
Overview
Development Signal
Development Signal · Emerging
Overview
Approval status
Investigational
Technology
Linker
cleavable linker; MT3-KN035-DOX High induced tumor apopt
MoA
Mechanism
targeting IL-4/IL-13 signaling
MoA
Biomarker
biomarker candidate and mechanistic hypothesis for anthracycline responsiveness
PK/PD
Half-life
3 h
PK/PD
Species
Rat
PK/PD
Animal (cat.)
Rat, In vitro
PK/PD
Experiment
PD
Toxicology
Species
Rat
Toxicology
Animal (cat.)
Rat, In vitro
Toxicology
Major finding
Design and Characterization of Thermosensitive Niosomes as Platforms for Daunorubicin Delivery.. Background/Objectives: The study describes the elaboration and evaluation of thermosensitive niosomes intended for the systemic application of daunorubicin hydrochloride. The attained stimulus sensitivity would determine the release of the chemotherapeutic predominantly at the target site, which ensure…
Toxicology
CRS
Reported
Clinical
Safety signal
Design and Characterization of Thermosensitive Niosomes as Platforms for Daunorubicin Delivery.. Background/Objectives: The study describes the elaboration and evaluation of thermosensitive niosomes intended for the systemic application of daunorubicin hydrochloride. The attained stimulus sensitivity would determine the release of the chemotherapeutic predominantly at the target site, which ensure…
Clinical
Reported OS
5
Clinical
Result source
ClinicalTrials.gov NCT04770272
Clinical
Program phase
PHASE_2
Clinical
Trial activity
No active/completed counts
Clinical
Trial ref
NCT04770272